PSYBF.US PsyBio Therapeutics Corp

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Oct 14, 2026
Market cap
USD 1.28K
P/E
-
P/B
202.42x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is PSYBF.US undervalued?

Graham number

The Graham number of PsyBio Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PsyBio Therapeutics Corp fundamental analysis

No fundamental analysis for PsyBio Therapeutics Corp yet.

PsyBio Therapeutics Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PsyBio Therapeutics Corp

PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company was incorporated in 2009 and is headquartered in Denver, Colorado.

Full company profile